• English
  • Sign In
  • Contact Us
×
Webinars » Effective gene editing using the CRISPR RNP system: higher editing efficiency, lower off-target effects, and minimal cytotoxicity

Effective gene editing using the CRISPR RNP system:higher editing efficiency, lower off-target effects, and minimal cytotoxicity

The CRISPR/Cas9 system has made targeted gene editing easily accessible for research and therapeutic purposes. The system utilizes Cas9 endonuclease, which is directed to its target DNA by a complementary crRNA:tracrRNA complex, or synthetic single guide RNA (sgRNA). Unlike previous generations of gene editing technology, CRISPR/Cas9 can be easily programmed to a desired genomic target, without the need for target-specific protein engineering.

Depending on the application, one of several delivery methods for the Cas9 protein and sgRNA may be appropriate; factors to consider include cost, ease of use, editing efficiency, tolerance for off-target effects, and cytotoxicity. Compared to sgRNAs generated via the more traditional method of in vitro translation (IVT), synthetic sgRNAs offer superior editing efficiency, flexibility, and ease of use. This webinar will discuss the advantages of using the CRISPR Ribonucleoprotein (RNP) delivery system to maximize the efficiency of CRISPR/Cas9-mediated editing.

Learning outcome from this webinar:

  • Why the CRISPR/Cas9 System is the appropriate gene editing technology for both research and therapeutic purposes.
  • How to choose the appropriate CRISPR/Cas9 delivery method, based on your downstream usage.
  • How the RNP system of delivery maximizes CRISPR/Cas9-mediated editing efficiency, and how to choose the appropriate grade of sgRNA for the desired application.

    James Chon
  • Speaker:
    James Chon, Ph.D. Field Application Scientist Genscript USA Inc.
  • Date:
    May 7th, 2020
  • Time:
    1pm EST | 10am PST

Speaker Bio

James Chon, Ph.D. is a Field Application Scientist with GenScript supporting its customized CRISPR reagents and services. James earned his Ph.D. in Molecular and Cellular Biology from Cornell University by studying deoxyuracil incorporation into DNA and its impact on different disease model systems. He then transitioned to GenScript in a sales support and now application scientist role. In his current work he supports researches using CRISPR for functional screening, animal model generation, and cell/gene therapies.